Pharmalittle: FDA delay forces a biotech to close; a Neurocrine deal
Good morning, everybody, and welcome to a different working week. We hope the weekend respite was stress-free and invigorating as ...
Good morning, everybody, and welcome to a different working week. We hope the weekend respite was stress-free and invigorating as ...
Alumis’s genomic analysis guided its improvement of envudeucitinib, a TYK2 inhibitor that some analysts now view as greatest at school. ...
This might be the largest week for biotech IPOs in years — even when the federal government stays shuttered quickly. ...
It’s not usually {that a} pharmaceutical government discusses a competitor’s success. Alkermes Chief Working Officer Blair Jackson not solely talks ...
For all of the benefit that radiopharmaceuticals offer, these treatments currently address a limited number of cancer targets. Aktis Oncology ...
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. ...
WASHINGTON — Health secretary Robert F. Kennedy Jr. and many top deputies are scheduled to speak alongside industry executives and ...
Bidding to buy metabolic medicines biotech Metsera in September came down to two pharmaceutical giants, with Novo Nordisk’s higher offer ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and ...
Prime Medicine, a biotech whose wild ambitions for a powerful gene editing technology sank as the biotech market slumped, announced Monday ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.